



1614/11W  
12.14

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Billot et al.

Serial No.: 10/521,508

Case No.: MC060YP

Filed: 11/18/2005

For: EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

By C. Donna Date 9/14/05  
MERCK & CO., INC.

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the official filing receipt received from the Patent and Trademark Office in the above application for which issuance of a corrected filing receipt is respectfully requested.

There is an error with respect to the title of the patent application the correct title is "EP4 Receptor Agonist, Compositions and Methods Thereof" a copy of the filing receipt indicating change, and a copy the transmittal letter is enclosed for your reference.

There is no fee believed due.


Respectfully submitted,

By [Signature]  
Sylvia A. Ayler, Reg. No. 36,436  
Attorney for Applicants  
MERCK & CO., INC.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-4909

Enclosures

Date: September 14, 2005

2006051



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/521,508	01/18/2005	1614	900	MC060P		15	2

000210  
 MERCK AND CO., INC  
 P O BOX 2000  
 RAHWAY, NJ 07065-0907

DOCKETED

SEP 07 2005

CHRISTINE A. CUFFE

CONFIRMATION NO. 2000  
 FILING RECEIPT  
 \*OC000000016762132\*  
 \*OC000000016762132\*

Date Mailed: 08/30/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Yongxin Han, Kirkland, CANADA;  
 John Colucci, Westmount, CANADA;  
 Xavier Billot, Montreal, CANADA;  
 Marie-Claire Wilson, Montreal, CANADA;  
 Robert Young, Senneville, CANADA;

Power of Attorney: The patent practitioners associated with Customer Number 000210.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/CA03/01306 08/25/2003  
 which claims benefit of 60/406,530 08/28/2002

## Foreign Applications

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No


SYLVIA A. AYLER

Early Publication Request: No

SEP 08 2005

PATENT DEPARTMENT

Title



~~Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma~~

EP4 Receptor Agonist, Compositions and Methods  
Thereof

Preliminary Class

514

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

### LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR

1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



U.S. PATENT AND TRADEMARK OFFICE  
U.S. DEPARTMENT OF COMMERCE

ATTORNEY'S DOCKET NUMBER  
MC060P

1) Docketed  
2) Filed

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)  
To be Assigned

INTERNATIONAL APPLICATION NO.  
PCT/CA2003/001306

INTERNATIONAL FILING DATE  
25 August 2003 (25.08.2003)

PRIORITY DATE CLAIMED  
28 August 2002 (28.08.2002)

**DOCKETED**

JAN 18 2005

TITLE OF INVENTION

EP4 Receptor Agonist, Compositions and Methods Thereof

APPLICANT(S) FOR DO/EO/US

Yongxin Han, John Colucci, Xavier Billot, Marie-Claire Wilson and Robert Young

**LORI SCHEPISI**

**Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:**

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
  2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
  3. ☐ This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission include items (5), (6), (9) and (21) indicated below.
  4. ☐ The US has been elected (PCT Article 31).
  5. ☒ A copy of the International Application as filed [35 U.S.C. 371(c)(2)]
    - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
    - b. ☐ has been communicated by the International Bureau.
    - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
  6. ☒ An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]
    - a. ☐ is attached hereto
    - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
  7. ☒ Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]
    - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
    - b. ☐ have been communicated by the International Bureau.
    - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
    - d. ☒ have not been made and will not be made.
  8. ☐ An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].
  9. ☒ An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].
  10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].
- Items 11 to 20 below concern other document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A preliminary amendment.
14. ☐ An Application Data Sheet under 37 CFR 1.76.
15. ☐ A substitute specification.
16. ☐ A power of attorney and/or change of address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT 1-18-05

EXPRESS MAIL NO. 969 589 730 05

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS

BEING DEPOSITED WITH THE UNITED STATES POSTAL

SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"

ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO

COMMISSIONER FOR PATENTS, P.O. BOX 1450,

ALEXANDRIA, VIRGINIA 22303-1450.

MAILED BY [Signature] DATE 1-18-05

<b>U.S. APPLICATION NO.</b> (If known, see 37 CFR 1.5) To be Assigned		<b>INTERNATIONAL APPLICATION NO.</b> PCT/CA2003/001306		<b>ATTORNEY'S DOCKET NUMBER</b> MC060P	
21. The following fees are submitted:  <input checked="" type="checkbox"/> a) Basic national fee..... <b>\$300.00</b> <input checked="" type="checkbox"/> b) Examination fee..... <b>\$200.00</b> <input checked="" type="checkbox"/> c) Search fee ..... <b>\$500.00</b>  <div style="text-align: right;"><b>TOTAL OF ABOVE CALCULATIONS = \$1000.00</b></div>				\$300.00 \$200.00 \$500.00 \$1000.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
63 - 100 =	0 / 50	0 = 0	X \$250.00	\$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)].					
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims		11 - 20 =	0	X \$50.00	\$0.00
Independent Claims		1 - 3 =	0	X \$200.00	\$0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+	\$360.00	
<b>TOTAL OF ABOVE CALCULATIONS (SUBTOTAL)</b>				<b>=</b>	<b>\$1,000.00</b>
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
<b>TOTAL NATIONAL FEE</b>				<b>=</b>	<b>\$1,000.00</b>
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				+	
<b>TOTAL FEES ENCLOSED</b>				<b>=</b>	<b>\$1,000.00</b>
				Amount to be refunded:	
				Amount to be charged:	

- a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 13-2755 in the amount of \$1,000.00 to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.


SEND ALL CORRESPONDENCE TO:

Customer No. 000210

MERCK & CO., INC.  
Patent Department, RY60-30  
P.O. Box 2000  
126 East Lincoln Avenue  
Rahway, New Jersey 07065-0970

DATE: January 18, 2005

PHONE #: (732) 594-4909

  
 SIGNATURE  
 Sylvia A. Ayler  
 NAME

36,436  
REGISTRATION NUMBER